Gini Fleming to Doxorubicin
This is a "connection" page, showing publications Gini Fleming has written about Doxorubicin.
Connection Strength
0.658
-
Phase II study of 96-hr continuous-infusion etoposide and doxorubicin with bolus cyclophosphamide in refractory epithelial ovarian cancer. Gynecol Oncol. 1997 Apr; 65(1):42-5.
Score: 0.139
-
Chemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancer: a Gynecologic Oncology Group Study. Cancer. 2010 Jan 15; 116(2):355-61.
Score: 0.084
-
The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study. Gynecol Oncol. 2007 Jul; 106(1):16-22.
Score: 0.071
-
Major progress for a less common cancer. J Clin Oncol. 2006 Jan 01; 24(1):6-8.
Score: 0.063
-
Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Ann Oncol. 2004 Aug; 15(8):1173-8.
Score: 0.058
-
Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study. J Clin Oncol. 2001 Feb 15; 19(4):1021-9.
Score: 0.046
-
A phase I study of liposomal doxorubicin (Doxil) with topotecan. Am J Clin Oncol. 2000 Jun; 23(3):297-300.
Score: 0.043
-
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer. Clin Cancer Res. 2020 03 01; 26(5):1009-1016.
Score: 0.042
-
High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study. Gynecol Oncol. 2017 08; 146(2):247-253.
Score: 0.035
-
An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2008 Jan; 108(1):3-9.
Score: 0.018
-
Impact of body mass index on treatment outcomes in endometrial cancer patients receiving doxorubicin and cisplatin: a Gynecologic Oncology Group study. Gynecol Oncol. 2007 Apr; 105(1):59-65.
Score: 0.017
-
Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group study. Br J Clin Pharmacol. 2006 Jul; 62(1):56-70.
Score: 0.017
-
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):976-83.
Score: 0.013
-
Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors. Ann Oncol. 2001 Dec; 12(12):1743-7.
Score: 0.012